ライフサイエンスコーパス: farnesoid X receptor

1 15 (FGF15), a target gene of the BA receptor farnesoid X receptor.

2 ogenous bile acids, indicating activation of farnesoid X receptor.

3 alized using a sensor based on the zebrafish farnesoid X receptor.

4 binding to the mammalian bile acid receptor farnesoid X receptor.

5 ired early growth response factor-1, but not farnesoid X receptor.

6 gene expression is regulated by the nuclear farnesoid X receptor.

7 factor-kappaB (NF-kappaB) rather than by the farnesoid X receptor.

8 dependent of the nuclear bile acid receptor, Farnesoid X receptor.

9 me-proliferated-activated receptor y and the farnesoid X receptor.

10 anscription of the gene (Nr1h4) encoding the farnesoid X receptor-1 (Fxr-1), thereby leading to reduc

11 The nuclear receptor FXR (farnesoid X receptor), a multiple functional transcripti

12 The bile acid receptor FXR (farnesoid X receptor) activates expression of fibroblast

13 thermore, restoring bile acid homeostasis by farnesoid X receptor activation markedly reduces PTB and

14 In contrast, obeticholic acid (OCA), a farnesoid X receptor agonist and second-line anti-choles

15 The farnesoid X receptor agonist EDP-305 reduces interstitia

16 cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients without cirrhos

17 Cilofexor is a nonsteroidal farnesoid X receptor agonist that demonstrated significa

18 t) as monotherapy or combined with TERN-101 (farnesoid X receptor agonist), in patients with presumed

19 5 agonist, INT-777 (50 muM), but not by the farnesoid X receptor agonist, GW4064 (10 muM).

20 Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve

21 Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefi

22 Further understanding of the role of farnesoid X receptor agonists and the potential role of

23 s of BS synthesis-suppressing drugs, such as farnesoid X receptor agonists, is greatest when optimal

24 ated receptor alpha (PPARalpha) and RXRalpha/farnesoid X receptor alpha (FXRalpha) heterodimeric nucl

25 ed receptor alpha (PPARalpha), RXRalpha plus farnesoid X receptor alpha (FXRalpha), liver receptor ho

26 Farnesoid X receptor alpha (FXRalpha, NR1H4) is a bile a

27 n, it appears that retinoid X receptor alpha/farnesoid X receptor alpha and liver receptor homolog 1

28 pathway inhibition induced the expression of farnesoid X receptor alpha, a transcription factor that

29 Bile acids and farnesoid X receptor also inhibited mouse HNF4alpha gene

30 s, has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile

31 lase most likely resulted from activation of farnesoid X receptor and induction of fibroblast growth

32 the orchestrated regulation mediated by the farnesoid X receptor and small heterodimer partner that

33 tant metabolic regulators acting through the farnesoid X receptor and TGR5 receptor.

34 dulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as

35 drug targets include the bile BA receptors, farnesoid X receptor and TGR5, the BA-induced gut hormon

36 Bile acids act on several receptors such as Farnesoid X Receptor and the G protein-coupled BA recept

37 The farnesoid X receptor and the liver X receptor (LXR) are

38 otohormones" for the retinoic acid receptor, farnesoid X receptor, and estrogen receptor.

39 ogen receptor-alpha, estrogen receptor-beta, farnesoid X receptor, and mast cells as possible targets

40 ptors, particularly the primary BA receptor, farnesoid X receptor, and small heterodimer partner, whi

41 imetastatic effects of guggulsterone (GS), a farnesoid X receptor antagonist, are linked to its abili

42 ry activities of the hepatic TR, NR1H4 (FXR; farnesoid X receptor), as our model system to tackle thi

43 Bile acid response was mediated by the farnesoid X receptor, as shown by the fact that overexpr

44 rs, recombinant FGF19, CCR2/CCR5 inhibitors, farnesoid X receptor bile acid receptor agonists, and no

45 The farnesoid X receptor/bile acid receptor (FXR) is a recen

46 efflux to lumen) and retinoic acid receptor/farnesoid X receptor (cholesterol catabolism).

47 , whereas deletion of the bile acid receptor farnesoid X receptor diminishes the effects of inulin.

48 Ablation of farnesoid X receptor dramatically increases enterohepati

49 t that overexpression of a dominant-negative farnesoid X-receptor eliminated the bile acid mediated d

50 d nuclear receptors (i.e., liver X receptor, farnesoid X receptor, estrogen receptor alpha, peroxisom

51 rol saturation index, a 2.5-fold increase in farnesoid X receptor expression, a 5-fold increase in LX

52 ed to sustained disruption of the intestinal farnesoid X receptor-fibroblast growth factor 15 axis, a

53 The farnesoid X receptor/fibroblast growth factor axis and i

54 DCs expressed the farnesoid X receptor for UDCA.

55 In particular, farnesoid X receptor (FXR) activation that revealed anti

56 everal microbe-derived bile acids attenuated farnesoid X receptor (FXR) activation, suggesting that l

57 notype in SIRT mice correlated with impaired farnesoid X receptor (FXR) activity due to persistent de

58 Nuclear receptor farnesoid X receptor (FXR) acts as a key regulator of bi

59 old, previously described as a key moiety in Farnesoid X receptor (FXR) agonism, herein we report the

60 eatment of mouse or human hepatocytes with a farnesoid X receptor (FXR) agonist GW4064 or bile acids

61 We showed that chronic BAs or farnesoid X receptor (FXR) agonist treatment of primary

62 omarker of pruritus in clinical trials of an farnesoid X receptor (FXR) agonist, cilofexor, in patien

63 Farnesoid X receptor (FXR) agonists are emerging as impo

64 tly contribute to hepatocytes, we identified farnesoid X receptor (FXR) agonists as inhibitors of BEC

65 The multimodal activities of farnesoid X receptor (FXR) agonists make this class an a

66 In an effort to develop orally active farnesoid X receptor (FXR) agonists, a series of tetrahy

67 cose cotransporter 2 (SGLT2) inhibitors, and farnesoid X receptor (FXR) agonists, with further novel

68 e acid profile, leading to the inhibition of farnesoid X receptor (FXR) and attenuation of scavenger

69 The nuclear farnesoid X receptor (FXR) and BA transporter mRNA expre

70 that GS can act as an antagonist ligand for farnesoid X receptor (FXR) and decrease expression of bi

71 A) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome prolifera

72 activator of the BA-sensing nuclear receptor farnesoid X receptor (FXR) and epigenetically up-regulat

73 bile acid-activated nuclear hormone receptor farnesoid X receptor (FXR) and G protein-coupled membran

74 Since farnesoid X receptor (FXR) and its natural ligands bile

75 in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic

76 metabolic homeostasis by activating nuclear farnesoid X receptor (Fxr) and membrane G-protein-couple

77 regulation mediated by the nuclear receptor farnesoid X receptor (FXR) and other effectors.

78 The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-a

79 e rodent Sult2A1 gene is also induced by the farnesoid X receptor (FXR) and pregnane X receptor (PXR)

80 The nuclear receptors, farnesoid X receptor (FXR) and pregnane X receptor (PXR)

81 dback loop operated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner

82 primarily regulated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner

83 id oxidation, and 3) decreased expression of farnesoid X receptor (FXR) and small heterodimer partner

84 Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner

85 oxicity in which mithramycin not only alters farnesoid X receptor (FXR) and small heterodimer partner

86 Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner

87 Cholestasis activates bile acid receptor farnesoid X receptor (FXR) and subsequently enhances hep

88 key regulators of liver biology: C/EBPalpha, Farnesoid X Receptor (FXR) and telomere reverse transcri

89 that the fed-state sensing nuclear receptor farnesoid X receptor (FXR) and the fasting transcription

90 roid metabolism not only share the receptors farnesoid X receptor (FXR) and the G protein-coupled bil

91 Bile acids also activate the farnesoid X receptor (FXR) and the G protein-coupled rec

92 are ligands for the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled rec

93 The farnesoid X receptor (FXR) and the liver x receptors (LX

94 The bile acid-activated receptors, nuclear farnesoid X receptor (FXR) and the membrane Takeda G-pro

95 Farnesoid X receptor (FXR) and the microRNAs miR-185, mi

96 metabolism and inflammation via the nuclear farnesoid X receptor (FXR) and the Takeda G protein-coup

97 ptome, bile acid-activated receptors nuclear farnesoid X receptor (FXR) and transmembrane G-protein-c

98 h mechanisms dependent on the microbiome and farnesoid X receptor (FXR) and type I interferon (IFN) s

99 tor-activated receptor-alpha (PPARalpha) and farnesoid X receptor (FXR) are activated in the fasted a

100 Liver X receptors (LXRs) and farnesoid X receptor (FXR) are nuclear receptors that fu

101 ism was likely independent of the microbiome-farnesoid X receptor (FXR) axis.

102 The farnesoid X receptor (FXR) belongs to a family of ligand

103 This ERalpha binding site overlaps the known farnesoid X receptor (FXR) binding site in the SHP promo

104 We have shown that activation of the farnesoid X receptor (FXR) blocks mineralization of bovi

105 the postprandial state, activation of ileal farnesoid X receptor (FXR) by bile salts results in tran

106 contribute to steatosis induced by diet and farnesoid X receptor (FXR) deficiency in both genders.

107 ether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are invol

108 we show that BAs that antagonize intestinal farnesoid X receptor (FXR) function, including tauro-bet

109 The farnesoid X receptor (FXR) functions as a bile acid (BA)

110 The nuclear receptor farnesoid X receptor (FXR) has been implicated in the co

111 Activation of the farnesoid X receptor (FXR) has indicated a therapeutic p

112 emic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new ther

113 ontrast to mice, human BSEP was regulated by farnesoid X receptor (FXR) in an isoform-dependent manne

114 The function of the farnesoid X receptor (FXR) in DKO mice was lower, reveal

115 ined through positive-feedback antagonism of farnesoid X receptor (FXR) in intestine and liver.

116 CYP7A1 transcription by bile acid-activated farnesoid X receptor (FXR) in its native promoter and ce

117 UCA) in the regulation of the orphan nuclear farnesoid X receptor (FXR) in vivo.

118 nd synthetic (i.e. GW4064) activators of the farnesoid X receptor (FXR) increased FGF21 gene expressi

119 Farnesoid X receptor (FXR) induces fibroblast growth fac

120 We found that farnesoid X receptor (FXR) inhibits expression of gankyr

121 e report that the nuclear bile acid receptor farnesoid X receptor (FXR) inhibits microRNA-34a (miR-34

122 Farnesoid X receptor (FXR) is a bile acid sensor that re

123 Farnesoid X receptor (FXR) is a bile acid sensor that re

124 Farnesoid X receptor (FXR) is a bile acid-activated tran

125 Farnesoid X receptor (FXR) is a bile acid-activated tran

126 Here we show that the farnesoid X receptor (FXR) is a direct regulator of ACE2

127 The farnesoid X receptor (FXR) is a member of the "metabolic

128 Farnesoid X receptor (FXR) is a member of the nuclear ho

129 The Farnesoid X receptor (FXR) is a member of the nuclear ho

130 Farnesoid X receptor (FXR) is a member of the nuclear re

131 The farnesoid X receptor (FXR) is a member of the nuclear re

132 The farnesoid X receptor (FXR) is a member of the nuclear re

133 The farnesoid X receptor (FXR) is a nuclear bile acid recept

134 The farnesoid X receptor (FXR) is a nuclear receptor (NR) kn

135 Farnesoid X receptor (FXR) is a nuclear receptor for bil

136 The farnesoid X receptor (FXR) is a nuclear receptor that ac

137 Farnesoid X receptor (FXR) is a nuclear receptor that ha

138 The farnesoid X receptor (FXR) is a nuclear receptor that pl

139 Farnesoid X receptor (FXR) is a promising target for non

140 Farnesoid X receptor (FXR) is an important regulator of

141 The nuclear bile acid receptor farnesoid X receptor (FXR) is an important transcription

142 Farnesoid X receptor (FXR) is considered a therapeutic t

143 ation of bile acid synthesis mediated by the farnesoid X receptor (FXR) is disrupted in the mutant mi

144 igand activated transcription factor nuclear farnesoid X receptor (FXR) is involved as a regulator in

145 Farnesoid X receptor (FXR) is the master regulator of bi

146 The farnesoid X receptor (FXR) is the transcriptional regula

147 rotection conferred by H(2) S was blocked by farnesoid X receptor (FXR) knockdown.

148 s were performed with islets from wild-type, farnesoid X receptor (FXR) knockout (KO), and beta-cell

149 The primary bile acid receptor farnesoid X receptor (FXR) maintains lipid and glucose h

150 Activation of farnesoid X receptor (FXR) markedly attenuates developme

151 dy, we show that LPS significantly decreases farnesoid X receptor (FXR) mRNA in mouse liver as early

152 Ligand-dependent SUMOylation of farnesoid X receptor (FXR) negatively regulates the expr

153 T-beta-MCA is an farnesoid X receptor (FXR) nuclear receptor antagonist,

154 cholestasis by altering the activity of the farnesoid X receptor (FXR) or by impairing the structure

155 As a cellular bile acid sensor, farnesoid X receptor (FXR) participates in regulation of

156 Intestinal farnesoid X receptor (FXR) plays a critical role in alco

157 The nuclear receptor farnesoid X receptor (FXR) plays a major role in the ent

158 Farnesoid X receptor (FXR) plays a pivotal role in the r

159 Farnesoid X receptor (FXR) plays an important role in ma

160 Farnesoid X receptor (FXR) plays important regulatory ro

161 Activation of the nuclear bile acid receptor farnesoid X receptor (FXR) protects against hepatic infl

162 Two-fold increase of BA-activated farnesoid X receptor (FXR) protein levels were seen in a

163 Constitutive activation of the farnesoid X receptor (FXR) reduces PPARgamma hepatic exp

164 The farnesoid X receptor (FXR) regulates bile acid, lipid an

165 um bile acids, and activation of the hepatic farnesoid X receptor (FXR) regulatory pathway.

166 The nuclear receptor farnesoid X receptor (FXR) shows potent antifibrotic act

167 ase (BSH) activity, inhibition of intestinal farnesoid X receptor (FXR) signaling and decreased tauro

168 ctivation in the liver of SCD mice inhibited farnesoid X receptor (FXR) signaling and its downstream

169 d hepatic macrophages to suppress hepatocyte farnesoid X receptor (FXR) signaling and promote PNAC.

170 d hepatic macrophages to suppress hepatocyte farnesoid X receptor (FXR) signaling and promote PNAC.

171 xamined, and expression of genes involved in farnesoid X receptor (FXR) signaling in the liver and in

172 The farnesoid X receptor (FXR) signaling pathway regulates b

173 Further, dietary TCDF inhibited the farnesoid X receptor (FXR) signaling pathway, triggered

174 SIRT1 iKO mice had reduced intestinal farnesoid X receptor (FXR) signaling via hepatocyte nucl

175 e acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling.

176 ctivate small heterodimer partner (SHP) upon farnesoid X receptor (FXR) stimulation by increasing BA

177 Activation of the farnesoid X receptor (FXR) suppressed liver CYP8B1 expre

178 re we report that Foxm1b is the first direct farnesoid X receptor (FXR) target gene known to be invol

179 ntified 7-oxo-DCA as a natural antagonist of Farnesoid X Receptor (FXR) to downregulate FXR signaling

180 that the MDR3 gene is trans-activated by the farnesoid X receptor (FXR) via a direct binding of FXR/r

181 given an intracerebroventricular infusion of farnesoid X receptor (FXR) Vivo-morpholino before AOM in

182 Farnesoid X receptor (Fxr)(-/-), small heterodimer partn

183 Our previous studies have shown that the farnesoid X receptor (FXR), a bile acid-activated nuclea

184 is and mutations in NR1H4, which encodes the farnesoid X receptor (FXR), a bile acid-activated nuclea

185 Farnesoid X receptor (FXR), a key regulator of hepatic e

186 signal through two major receptor pathways: farnesoid X receptor (FXR), a member of the nuclear horm

187 The farnesoid X receptor (FXR), a member of the nuclear horm

188 ne is a highly efficacious antagonist of the farnesoid X receptor (FXR), a nuclear hormone receptor t

189 Here we show that the farnesoid X receptor (FXR), a nuclear receptor for bile

190 is strongly up-regulated by agonists of the farnesoid X receptor (FXR), a nuclear receptor for bile

191 and-binding domain (LBD) of human and murine farnesoid X receptor (FXR), a nuclear receptor for bile

192 t studies to serve as a binding site for the farnesoid X receptor (FXR), a nuclear receptor for bile

193 n of hepatic SIRT1 reduces the expression of farnesoid X receptor (FXR), a nuclear receptor that regu

194 is mediated through the bile acid-activated farnesoid X receptor (FXR), a recently characterized mem

195 bile acids are physiological ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor.

196 sodium-dependent bile acid transporter, the farnesoid X receptor (FXR), and familial intrahepatic ch

197 This effect was mediated through the farnesoid X receptor (FXR), as demonstrated in Fxr(-/-)

198 In IBD patients, bile acids, their receptor farnesoid X receptor (FXR), IL-33, and eosinophils were

199 The nuclear bile acid receptor, farnesoid X receptor (FXR), is an important regulator of

200 The nuclear bile acid receptor, farnesoid X receptor (FXR), is an important transcriptio

201 Expression of nuclear receptors farnesoid X receptor (FXR), LXRalpha, liver receptor hom

202 luding those of nuclear receptors, primarily farnesoid X receptor (FXR), membrane BA receptors, and F

203 mice with intestine-specific knockout of the farnesoid X receptor (FXR), mice that express an FXR tra

204 Farnesoid X receptor (FXR), or NR1H4, protects the liver

205 Enterohepatic nuclear receptors including farnesoid X receptor (FXR), pregnane X receptor (PXR), a

206 Geniposide also down-regulated expression of Farnesoid X receptor (FXR), small heterodimer partner (S

207 herapies include pharmacological agonists to farnesoid X receptor (FXR), the master regulator of hepa

208 Although bile acids activate the farnesoid X receptor (FXR), the mechanism underlying bil

209 Farnesoid X receptor (FXR), the primary bile acid-sensin

210 holesterol, liver X receptors (LXRs) and the farnesoid X receptor (FXR), together with other members

211 n of BSEP gene expression is mediated by the farnesoid X receptor (FXR), which binds as a heterodimer

212 The farnesoid X receptor (FXR), which is activated by bile a

213 ntagonist ligands for the bile acid receptor farnesoid X receptor (FXR), which is an important regula

214 al and transactivational regulator of murine farnesoid X receptor (Fxr), which is the primary bile ac

215 An antagonist of bile acid receptor farnesoid X receptor (FXR), Z-guggulsterone, reduced the

216 gulates triglyceride metabolism through both farnesoid X receptor (FXR)-dependent and -independent pa

217 Cholate treatment was associated with a farnesoid X receptor (FXR)-dependent increase in hepatic

218 isk of statins is coupled to the activity of farnesoid X receptor (FXR)-dependent signaling pathways

219 ntracellular bile acids results in repressed farnesoid X receptor (FXR)-FGF15 signalling, leading to

220 The farnesoid X receptor (FXR)-fibroblast growth factor 19 (

221 pact of sulfated progesterone metabolites on farnesoid X receptor (FXR)-mediated bile acid homeostasi

222 Terminal ileal farnesoid X receptor (FXR)-mediated gene expression and

223 Chenodeoxycholic acid (CDCA) and the farnesoid X receptor (FXR)-specific agonist GW4064 stron

224 Suppressing farnesoid X receptor (FXR)-the receptor of GUDCA-allevia

225 acids and transactivated by nuclear receptor farnesoid X receptor (FXR).

226 (PPAR) family, liver X receptors (LXRs), and farnesoid X receptor (FXR).

227 GP-BAR1, and nuclear receptors, such as the farnesoid X receptor (FXR).

228 C) acutely enhance insulin secretion via the farnesoid X receptor (FXR).

229 in part through their binding to the nuclear farnesoid X receptor (FXR).

230 y by downregulating the transcription factor farnesoid X receptor (FXR).

231 ve been identified as potent agonists of the farnesoid X receptor (FXR).

232 1 (FIC1)] posttranslationally activated the farnesoid X receptor (FXR).

233 tagonism of the receptor for bile acids, the farnesoid X receptor (FXR).

234 regulated by ligands of the nuclear receptor farnesoid X receptor (FXR).

235 hat bile acids are physiological ligands for farnesoid X receptor (FXR).

236 activating nuclear receptors, including the farnesoid X receptor (FXR).

237 h the bile salt-binding transcription factor farnesoid X receptor (Fxr).

238 ing signaling by the intestinal BA receptor, farnesoid X receptor (FXR).

239 independently of its canonical receptor, the farnesoid X receptor (FXR).

240 in inhibited bile-mediated activation of the farnesoid X receptor (FXR).

241 cirrhosis and liver cancer also have reduced farnesoid X receptor (FXR).

242 molecules that activate the nuclear receptor farnesoid X receptor (FXR).

243 re ligands for the nuclear hormone receptor, farnesoid X receptor (FXR).

244 responses dependent on the nuclear receptor Farnesoid X Receptor (FXR).

245 le acid (TBA) levels, which are regulated by farnesoid X receptor (FXR)/FGF15.

246 The intestinal farnesoid X receptor (FXR)/fibroblast growth factor 19 (

247 ation and bile acid metabolism by modulating farnesoid X receptor (FXR); we here investigate its role

248 r receptors PPARalpha (encoded by NR1C1) and farnesoid X receptor (FXR, encoded by NR1H4) are activat

249 Farnesoid X receptor (FXR, NR1H4) is a bile acid-activat

250 The farnesoid X receptor (FXR, NR1H4) is a bile acid-respons

251 Activation of farnesoid X receptor (Fxr, Nr1h4) is a major mechanism i

252 Farnesoid X receptor (FXR, NR1H4) is a member of the nuc

253 gulating the transcriptional activity of the farnesoid X receptor (FXR, NR1H4), otherwise known as th

254 ation of the nuclear and membrane receptors, farnesoid X receptor (FXR-alpha) and TGR5 (G-protein-cou

255 The bile acid (BA) nuclear receptor, farnesoid X receptor (FXR/NR1H4), maintains metabolic ho

256 G37) and nuclear hormone receptors including farnesoid X receptor (FXR; also known as NR1H4).

257 The bile acid receptor farnesoid X receptor (FXR; NR1H4) is a central regulator

258 The farnesoid X receptor (FXR; NR1H4) is an intracellular bi

259 The farnesoid X receptor (FXR; NR1H4) regulates bile acid an

260 lic acid, and deoxycholic acid activated the farnesoid X receptor (FXR; NR1H4), an orphan nuclear rec

261 he decreased sensitivity of mice lacking the farnesoid X receptor (FXR; nuclear receptor subfamily 1,

262 l, a coffee diterpene, is a known agonist of farnesoid X receptors (FXR), which are involved in chole

263 that the class II nuclear hormone receptor, farnesoid X-receptor (FXR), incorporates histone methylt

264 and transfected with expression plasmids for farnesoid X-receptor (FXR), short heterodimer partner (S

265 d to isolate genes that are regulated by the farnesoid X-receptor (FXR, NR1H4).

266 To address the importance of the farnesoid X-receptor (FXR; NR1H4) for normal cholesterol

267 regulation is provided by bile acids through farnesoid-X-receptor (FXR) (NR1H4).

268 nd obeticholic acid (OCA, 6-a-ethyl-CDCA), a farnesoid-X-receptor (FXR) agonist, as preventive treatm

269 antagonist of the mammalian bile acid sensor farnesoid-X-receptor (FXR).

270 (FGF) 19 levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin-like phosp

271 eptor subfamily 1 group H member 4 (NR1H4 or farnesoid X receptor [FXR]) regulates bile acid synthesi

272 tein directly activated by cAMP 2 (Epac2) or farnesoid X receptor (FXR2) was ruled out by experiments

273 me proliferator-activated receptors (PPARs), farnesoid X receptors (FXRs), liver X receptors (LXRs),

274 is mediated through the retinoid X receptor/farnesoid X receptor heterodimer and is independent of b

275 Interestingly, the expression levels of farnesoid X receptor in liver and intestine were signifi

276 ory factor analysis implicated the bile acid/farnesoid X receptor in some of these processes.

277 These compounds agonized the farnesoid X receptor in vitro, and mice gavaged with the

278 nd suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the

279 Ablating one receptor, the farnesoid X receptor, in DCs enhanced the generation of

280 4), a small-molecule nonsteroidal agonist of farnesoid X receptor, in patients with nonalcoholic stea

281 of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreas

282 1 (LSD1) is directly induced by BA-activated farnesoid X receptor, is recruited to the BA synthetic g

283 Farnesoid X receptor knockout mice (with a hydrophilic B

284 p7b1, and produces partial resistance to the farnesoid X receptor, leading to a lithogenic bile salt

285 abetic Patients with NASH Trial (PIVENS) and Farnesoid X Receptor Ligand Obeticholic Acid in NASH Tre

286 ersus placebo-treated patients in the FLINT (farnesoid X receptor ligand obeticholic acid in NASH tri

287 The farnesoid X receptor ligand obeticholic acid in the NASH

288 Thus, farnesoid X receptor-mediated regulation was preserved.

289 1, higher Srepb2 messenger RNA (mRNA), lower farnesoid X receptor (Nr1h4) mRNA, and lower Cyp7a1 mRNA

290 r-1 null (Tgr5(-/-)) and intestinal-specific farnesoid X receptor null (Fxr(Delta/E)) mice on high-fa

291 In addition, ASBT expression in farnesoid X receptor null mice was unresponsive to bile

292 pd3 expression was attenuated in LCA-treated farnesoid X receptor-null mice that are resistant to LCA

293 d B6J mice, including the bile acid receptor farnesoid X receptor, oxysterol 7alpha-hydroxylase, ster

294 Furthermore, bile acids and farnesoid X receptor reduced the expression of nuclear H

295 receptor (LXR)/retinoid X receptor (RXR) and farnesoid X receptor/RXR nuclear receptor signaling amon

296 Farnesoid X receptor; Small Heterodimer Partner double k

297 ulation of ASBT by bile acids is mediated by farnesoid X receptor via small heterodimer partner-depen

298 ty to modulate bile acid activated proteins: farnesoid X receptor, vitamin D receptor, pregnane X rec

299 Intestinal farnesoid X receptor was up-regulated after 21 days of C

300 deoxycholic acid, the natural agonist of the farnesoid X receptor, which is a nuclear hormone recepto